Application of AGEs inhibitor in preparation of medicine for reducing colorectal polyp and lung nodule canceration risk

Abstract

The invention discloses application of an AGEs inhibitor in preparation of a medicine for reducing colorectal polyp and lung nodule canceration risks. Through the application of the AGEs inhibitor, the canceration risk of colorectal polyps and lung nodules is remarkably reduced. The ECM density is reduced by reducing AGEs modification, so that immune cells can more effectively permeate into a lesion area, the local immune surveillance and defense capability is enhanced, and an innovative and effective intervention means is provided for early prevention of cancers.

Description

Technical Field

[0001] This invention relates to the application of AGEs inhibitors in the preparation of drugs that reduce the risk of colorectal polyps and lung nodules becoming cancerous, and belongs to the field of tumor immunotherapy technology. Background Technology

[0002] Colorectal polyps and pulmonary nodules are common benign lesions in clinical practice, usually discovered during routine physical examinations. However, some polyps and nodules can evolve into malignant tumors under certain conditions, a process known as "carcinogenesis." The risk is mainly related to the enlargement of the lesion and abnormal cell activity. Currently, most treatments for polyps and nodules are based on "observational therapy," meaning that after the lesion is discovered, it is monitored regularly until it further enlarges or worsens, at which point surgical removal or other treatments are performed. This "passive observation" model cannot effectively grasp the "window period" of cancer risk, leading to aggressive treatment measures only being taken when the lesion shows a significant tendency to become cancerous. By this time, the patient may have missed the optimal intervention opportunity, increasing the complexity and difficulty of treatment.

[0003] Existing studies have shown that structural changes in the extracellular matrix (ECM), particularly collagen densification, are closely related to the risk of carcinogenesis and can serve as an indicator of the risk of polyps and nodules becoming cancerous. Collagen densification significantly impacts the permeability of immune cells, hindering their effective migration, weakening their immune surveillance and ability to kill diseased cells, and increasing the risk of carcinogenesis. Nodules and high-risk polyps are often accompanied by the accumulation of AGEs (advanced glycosylation end products). AGEs modification of collagen makes collagen and other components more compact, altering the physical properties of the area and making it difficult for immune cells to effectively enter and monitor these regions. This weakens the defense and clearance of early-stage cancer, increasing the risk of nodules and polyps becoming cancerous. Therefore, inhibiting AGEs modification and slowing ECM densification may improve the local immune environment, enhance the surveillance and killing functions of immune cells, and thus reduce the probability of nodules and polyps becoming cancerous.

[0004] In recent years, studies have found that AGEs inhibitors (such as aramid (ALT-711) and all-trans retinoic acid (RA) can reduce the modification of ECM components such as collagen by AGEs, thereby reducing the densification level of the ECM. However, AGEs inhibitors are mainly used to treat cardiovascular diseases, respiratory diseases, nutritional and metabolic diseases, female urogenital diseases, and pregnancy complications. There is currently no treatment method that reduces the risk of polyp and nodule carcinogenesis by inhibiting collagen AGEs modification. Based on this, this invention proposes a method to reduce collagen AGEs modification in colorectal polyps and pulmonary nodules using AGEs inhibitors, thereby optimizing the local immune environment, enhancing the activity and migration of immune cells, and reducing the risk of carcinogenesis. Summary of the Invention

[0005] The purpose of this invention is to provide the application of AGEs inhibitors in the preparation of drugs that reduce the risk of colorectal polyps and lung nodules becoming cancerous. By inhibiting AGEs modification to reduce ECM densification, the activity and permeability of local immune cells are improved, immune defense is enhanced, and the occurrence of cancer is prevented.

[0006] Preferably, the AGEs inhibitor is arachidonic acid (ALT-711).

[0007] Preferably, the dose of the AGEs inhibitor is 10 mg / day of arachidonic acid.

[0008] Preferably, the drug is indicated for patients with colorectal polyps or pulmonary nodules at high risk of malignant transformation, and the drug is administered orally or intravenously.

[0009] Preferably, the ECM density, AGEs modification, and immune cell penetration of the submucosa and lamina propria are monitored regularly after drug administration.

[0010] This invention significantly reduces the risk of malignant transformation of colorectal polyps and pulmonary nodules through the application of AGEs inhibitors. By reducing AGEs modification and lowering ECM density, immune cells can more effectively penetrate the lesion area, enhancing local immune surveillance and defense capabilities, thus providing an innovative and effective intervention for early cancer prevention. Attached Figure Description

[0011] Figure 1 The images show microscopic imaging results of clinical samples with cancerous changes. Blue represents the cell nucleus, and gold represents collagen.

[0012] Figure 2 The study included the collagen content, distribution, and immune cell infiltration in the model mouse tissues before and after treatment. Detailed Implementation

[0013] The present invention will be further described below with reference to the embodiments, but the description of the embodiments does not limit the scope of protection of the present invention in any way.

[0014] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. The terminology used herein in the description of the invention is for the purpose of describing particular embodiments only and is not intended to limit the invention. Furthermore, while this document may provide examples of parameters containing specific values, it should be understood that the parameters need not be exactly equal to the corresponding values, but may approximate the corresponding values ​​within acceptable error tolerances or design constraints.

[0015] Unless otherwise specified, all substances or instruments used in the following examples can be obtained from conventional commercial sources.

[0016] Example 1: AGEs inhibitors reduce the risk of colorectal polyps becoming cancerous. (1) Sample selection: Colorectal polyps with a high risk of malignant transformation were selected from screened patients or mouse models. Imaging and pathological analysis confirmed that the polyps had high ECM density, especially significant collagen densification in the submucosa and lamina propria. Figure 1 ).

[0017] (2) Application of AGEs inhibitors: Patients or model mice were given alanine chloride (ALT-711) as an AGEs inhibitor at a dose of 10 mg daily for 1 week.

[0018] (3) Local immune environment assessment: Before and after treatment, the collagen density and immune cell infiltration of the submucosa and lamina propria were assessed by pathological section staining. Figure 2 ).

[0019] (4) Effect evaluation: One month after treatment, imaging examinations showed a significant reduction in the risk of cancer and a decrease in the incidence of tumors.

[0020] Example 2: AGEs inhibitors reduce the risk of cancerous transformation of lung nodules (1) Sample selection: lung nodules with high risk of cancer were screened from patients undergoing physical examinations and confirmed by imaging examinations.

[0021] (2) AGEs inhibitor application: High-risk patients were given alanine chloride (ALT-711) at a dose of 10 mg daily for 1 week.

[0022] (3) Local immune environment assessment: The density of ECM and the activity of immune cells before and after AGEs modification were observed through imaging and tissue analysis.

[0023] (4) Risk assessment: The results showed that after AGEs modification was reduced, the density of ECM decreased, the activity and migration of local immune cells were enhanced, and the risk of carcinogenesis was significantly reduced.

[0024] The above embodiments are only for illustrating the technical concept and features of the present invention. Their purpose is to enable those skilled in the art to understand the content of the present invention and implement it accordingly. They should not be used to limit the scope of protection of the present invention. All equivalent changes or modifications made in accordance with the spirit and essence of the present invention should be covered within the scope of protection of the present invention.

Claims

1. Application of AGEs inhibitors in the preparation of drugs that reduce the risk of colorectal polyps or lung nodules becoming cancerous.

2. The application according to claim 1, characterized in that, The AGEs inhibitor is arachidonic acid.

3. The application according to claim 2, characterized in that, The dosage of AGEs inhibitors is 10 mg / day of arachidonic acid.

4. The application according to claim 2, characterized in that, The medication can be administered orally or intravenously.

5. The application according to claim 2, characterized in that, After drug administration, the ECM density, AGEs modification, and immune cell penetration of the submucosa and lamina propria were monitored regularly.

Images